Ekf Diagnostics Share Discussion Threads

[wan] 04/3/2021 07:45

PrimeStore® Molecular Transport Medium (MTM) was invented in 2006 in preparation for a worldwide pandemic, which at the time was expected to be H5N1 influenza. It was designed to rapidly inactivate viruses, bacteria and pathogens within the sample and stabilize the RNA and DNA to provide safer and more efficient workflow for molecular testing and sequencing. I note that the Executive Vice President Global Business Development at Longhorn Vaccines highlighted the following recent ThermoFisher article - Rapid Genetic Sequencing for COVID-19 Global Surveillance By Behind The Bench Staff 03.01.2021 With more strains of SARS-CoV-2 appearing in communities across the globe, there is a growing call for national and international collaboration to understand these variants, including whether any are more infectious and how they are spreading. While PCR is a very important and scalable tool that is being used extensively in labs across the globe for diagnosis of COVID, it cannot provide deep insight into the virus’s full genome – this is where the advanced technology of next-generation sequencing (NGS) comes into play. Last March, Thermo Fisher Scientific introduced the Ion AmpliSeq SARS-CoV-2 Research Panel to aid in COVID-19 epidemiological research and contact tracing efforts using rapid NGS. Labs around the world have been using the panel to study how the virus is transmitted and decipher changes in its genetic code. Now, recognizing the pressing need to ramp up efforts to identify and track the newly identified strains, as well as emerging variants, additional clinical laboratory directors are joining global efforts to identify variants among patients who test positive for COVID-19. Q: Why is there a growing urgency to ramp up SARS-CoV-2 sequencing efforts? This urgency has come partly from realizing that here in the United States, we had only sequenced a fraction of the genomes necessary to identify and track strains. The combination of regulatory initiatives and proposed legislation to fund surveillance with up to $2BN has drawn growing awareness and demand for wider-spread sequencing. Full article - hTTps://www.thermofisher.com/blog/behindthebench/rapid-genetic-sequencing-for-covid-19-global-surveillance/

[tongosti] 03/3/2021 21:27

I always say that am completely agnostic re direction of my next trade. If there is indeed further upside as you say then sure as day I will jump back in as soon as Mr Market breaks out North. Until then - not really a fan of giving the tape the benefit of the doubt.

[srichardson8] 03/3/2021 19:30

never a truer word written

[rivaldo] 03/3/2021 18:43

No need - imo there's still lots of upside here. Run your winners.....that's how I've done so well since I started this lark.

[tongosti] 03/3/2021 18:14

HahahaDid you cash in before the share price came to a grinding halt? Lol.

[rivaldo] 03/3/2021 15:35

Cheers pal :o)) Actually it worked last time too - just look at the rising chart from early September to November last year and you'll get the idea.....

[tongosti] 03/3/2021 13:48

You were also expecting the exact same following the last one, if memory serves? Hopefully second time lucky pal.

[rivaldo] 03/3/2021 11:47

I'd expect a nice run-up in the share price prior to the results on 30th March - and hopefully afterwards! Particularly given the year end trading statement: Https://www.investegate.co.uk/ekf-diagnostics-hldg--ekf-/rns/trading-update/202101120700063139L/ " Full year performance expected to be comfortably ahead of upgraded market consensus Q1 2021 performance to materially exceed management expectations EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care business, confirms that continued strong trading will result in the performance for the year ending 31 December 2020 being comfortably ahead of already upgraded market expectations..... ....With continued strong performance in the core business and a number of indicative orders for PrimeStore MTM for the first quarter 2021 that are likely to be realised, the Board is confident that performance for the first quarter of 2021 will be materially ahead of current management expectations, and the first quarter of 2020."

[tongosti] 03/3/2021 10:03

Good timekeeping today pal - 7:36. Well done.

[wan] 03/3/2021 07:36

An interesting comparison - Last years Notice of FY Results announcement contained the following description - About EKF Diagnostics Holdings plc ( www.ekfdiagnostics.com ) EKF is a leading point-of-care diagnostics and central laboratory assay manufacturer with an estimated 80,000 hemoglobin, hematocrit, HbA1c, glucose and lactate analyzers in regular use across more than 100 countries. EKF specializes in developing tests for use in anemia and diabetes diagnosis and management, as well as providing a portfolio of reagents for use in clinical chemistry analyzers. hTTps://uk.advfn.com/stock-market/london/ekf-diagnostics-EKF/share-news/EKF-Diagnostics-Holdings-PLC-Notice-of-Results/81906145 Todays announcement contains the following description - About EKF Diagnostics Holdings plc ( www.ekfdiagnostics.com ) EKF Diagnostics Holdings plc specialises in the development, production and worldwide distribution of point-of-care analyzers and clinical chemistry reagents for use in hospital and research laboratories, doctor's offices, blood banks and for in-field anaemia screening programmes. EKF is also a bulk manufacturer of enzymes and has custom manufacturing facilities in the USA for a variety of life science products. In 2020, EKF developed a range of COVID-19 testing products including PrimeStore MTM, an FDA-approved and CE marked sample containment device that allows the safe handling, transportation and analysis of test swabs and samples, which it manufactures under licence, and COVID-SeroKlir, a leading ELISA-based antibody test from Kantaro Biosciences that provides a precise measurement of COVID-19 IgG antibodies. hTTps://uk.advfn.com/stock-market/london/ekf-diagnostics-EKF/share-news/EKF-Diagnostics-Holdings-PLC-Notice-of-Results/84481970 In my opinion only, this further supports my view that PrimeStore products will become core EKF products i.e. in constant use for the foreseeable (as perhaps exemplified by SBI's expansion in the US), and in that I also include country surveillance and preparedness.

[wan] 03/3/2021 07:21

And....EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care business, will announce its preliminary results for the year ended 31 December 2020 on Tuesday 30 March 2021.

[wan] 03/3/2021 07:18

I note Source Bio's news today - 03 March 2021 RNS REACH SourceBio International plc ("SourceBio", the "Company" or the "Group") US expansion of COVID-19 testing services COVID-19 testing services to be offered from San Diego facilities SourceBio International plc (AIM: SBI), the international provider of integrated state-of-the-art laboratory services and products , announces that its laboratory operations in San Diego, California, are to be expanded to include COVID-19 qPCR testing services. The division based in the Torrey Pines Genomics hub of the US, and home to prestigious as the Scripps Research Center, will mirror that of the Company's set up in Nottingham, England, and is expected to be fully operational in Q2 2021. The Group's existing San Diego facility currently houses Stability Storage Solutions and Genomics business units and the enhanced space is planned to have the capacity to process up to circa 5,000 samples per day with opportunities for continued growth. SourceBio already has cGMP, HPRA and FDA accredited facilitates in the UK, Ireland and United States for a global client base. The increased laboratory capacity of 1642 square feet will adhere to requirements and be fully compliant with guidelines from the FDA. The Company expects to receive the necessary accreditation to begin processing samples within the planned timeframe. The site will also benefit from the available local labour pool which is rich in healthcare and research talent. The Company is to employ additional staff onsite who will be needed to operate a 24/7 service. The laboratory will not only serve the local community but also support SourceBio's global partners across the United States. Jay LeCoque, Executive Chairman, commented: "SourceBio has already processed approaching 1,000,000 COVID-19 antigen RT-PCR tests in the UK for the DHSC and the NHS, Private Hospital Groups and Commercial customers since first offering its service in May 2020. "This further investment in our San Diego facility increases our overall capacity to increase COVID-19 qPCR testing services by up to an additional 5,000 samples per day and means we can address the clear market demand for COVID-19 testing in the US." Full release - hTTps://uk.advfn.com/stock-market/london/sourcebio-SBI/share-news/SourceBio-International-PLC-US-expansion-of-COVID/84481983

[tongosti] 02/3/2021 18:34

You better hope share prices does not touch 60 now wan as so far the market has refused to take your daily posts into account.I received so much stick early Nov last year when I said the share price was ahead of itself. I guess this is quite an emotional game for most. It shouldn't as this game is the hight of capitalism. Fiercely competitive. Cold blooded logic only works.

[wan] 02/3/2021 10:14

Mirandaj...I also didn't like the way Innova was reported by some and that certain marketing appeared to come across as if it was a British test......it took only a short investigation to understand that it is ultimately a Chinese product (and not even a US product as some thought, but apparently supplied by a US hedge fund!). Ultimately, no doubt the public inquiries will eventually make for interesting reading! I note from the contracts awarded to Innova that it appears the UK Government has a very large stock of these tests (soon get through them via routine school/college testing etc). However and in my opinion only, given recent developments, it's likely that Innova's time in the UK market will not last too much longer. Lateral flow tests do have a part to play in my view, as will other rapid tests, such as rapid extraction-free PCR tests, and indeed highly accurate, high throughput PCR and extraction-free antigen laboratory tests. And this is where PrimeStore products could potentially see increased usage, as ultimately a sample collection will be required in some format or another for all tests, e.g. saliva or nasal/throat swab. And of course, a tie-in/enabling product with a global test manufacturer/developer would also be well received.

[mirandaj] 02/3/2021 08:12

"In My View... Home testing is a waste of time In an ideal world, all tests would be 100 per cent accurate — but they aren’t. And when it comes to determining whether you are carrying Covid-19, you need to be able to have faith in the results. Yet the Innova lateral flow tests, which we are told will be sent out to those with children at school or college, but also to bus drivers and teachers, for example, are barely fit for purpose. They were recently tried out in a mass-testing exercise in Liverpool, but failed to detect 60 per cent of cases. The issue lies largely with the way the test is used. I’ve never yet seen one done properly on news bulletins. The swab should be passed backwards along the floor of the nose (ie. parallel to the soles of the feet) for about the length of a matchstick. This is unpleasant. The proposal to increase home testing underestimates the potential harms if faulty data is collected; it will only be of value if asymptomatic people who are infectious are detected and isolated, and their contacts traced. There is a solution to this emerging chaos: abandon the Innova tests and utilise the simple saliva test, which is widely used in Austria." https://www.dailymail.co.uk/health/article-9313835/Will-honey-drops-ease-red-itchy-eyes-Dr-MARTIN-SCURR-answers-health-questions.html

[wan] 02/3/2021 07:52

Staying with the US - CMS moves to stop COVID-19 testing denials, cost sharing in private plans March 1, 2021 CMS has built upon the order with guidance that details when testing needs coverage. ACLA, a laboratory trade group representing Quest Diagnostics and LabCorp, praised the move as "decisive action" that takes "critical steps to close coverage gaps" and protect patient access to COVID-19 testing. Other parts of the new document state that insurers have to cover point-of-care tests and COVID-19 diagnostic tests provided through state- or locality-administered sites. No cost sharing is permitted. America's Health Insurance Plans, which represents insurers including Aetna and Anthem, also commented on the guidance. "Since the beginning of the COVID-19 crisis, health insurance providers have worked with hospitals, health providers, and others to ensure that Americans have access to the prevention, testing, and treatment needed to overcome COVID-19, and that cost is not a barrier. Working together, we must expand and increase COVID-19 testing," AHIP spokesperson David Allen said. Full story - hTTps://www.medtechdive.com/news/cms-moves-to-stop-covid-19-testing-denials-cost-sharing-in-private-plans/595862/

[tongosti] 02/3/2021 07:51

What a theme - pinning hopes on virus mutations for the share price to go higher. You're sure it's ethical?PS. Have you checked a correlation chart between ekf and wider markets since 9nov (Pfizer vaccine announcement day)? It basically rubbishes the same old thesis being paraded on this board incessantly.

[wan] 02/3/2021 07:48

Covid-19 variants pose 'real threat' to vaccine progress, CDC warns Published4 hours ago The spread of highly contagious coronavirus variants is threatening to fuel a "potential fourth surge of cases" in the US, a top health official has warned. The head of the US Centers for Disease Control and Prevention (CDC) said she was concerned by recent Covid-19 data. Dr Rochelle Walensky said about 70,000 new cases a day had been recorded last week - "a very high number". There were nearly 2,000 deaths a day in the same period, she added. "Please hear me clearly: at this level of cases, with variants spreading, we stand to completely lose the hard-earned ground we have gained," Dr Walensky said. "These variants are a very real threat to our people and our progress." There are many different versions, or variants, of Covid-19 circulating, but health experts are particularly concerned about a few which appear to be more contagious, including those first detected in the UK, South Africa and Brazil. Given this, Dr Walensky said she was "really worried" about reports of US states "rolling back the exact public health measures we have recommended to protect people from Covid-19". "We have the ability to stop a potential fourth surge of cases in this country. Please stay strong in your conviction," she said. Full story - hTTps://www.bbc.co.uk/news/world-us-canada-56247656

[tongosti] 02/3/2021 07:04

Morning Wan - what have you got for us this morning?

[james188] 01/3/2021 17:25

Just sign up to the free RNS alert service on Investegate or similar and you will be told when the results will come out. You can also check back to historic RNS announcements to see what happened in previous years.The company's PR company - Walbrook - are also very good at providing latest information. Again, you can sign up free of charge.

[srichardson8] 01/3/2021 16:48

though they had originally been scheduled for 24th March when they ended up giving a detailed trading update prior to the full release as above. They will let us know a while beforehand.

[cambridgedon] 01/3/2021 16:12

Please can someone remind me when results are due. Thanks, CD

[petewy] 01/3/2021 15:34

Wan I too read your posts avidly

[btgman] 01/3/2021 14:03

Wan Keep posting EKF is getting in to the window for results when all will be revealed AIMHO GLA BTG

[wan] 01/3/2021 12:56

Thanks Cambridgedon. All sorts of people will no doubt come and go on here, but sometimes I just don't want to, or indeed need to, get into any debate/response. As EKF's CEO, Julian Baines, told those at the meeting back in December (only a handful of us were in attendance), he was confident that the opportunities presenting to EKF (which are many beyond Covid-19) will ultimately deliver to investors over time, and referred to the share price trend this year as an example. And that's what this thread is mainly about i.e. understanding/discussing the long term investment proposition in EKF. I have said previously that it's absolutely fine seeing/reading alternative views, but short term trading opportunities (either way) is not likely to get much traction/discussion on this thread. That's not to suggest the likes of Tongosti should stop posting, it's just that short term is really not of much interest to most readers, hence a predominantly zero response policy from me, even when being goaded/provoked.